Indoco Remedies Statistics
Total Valuation
Indoco Remedies has a market cap or net worth of INR 20.89 billion. The enterprise value is 31.38 billion.
| Market Cap | 20.89B |
| Enterprise Value | 31.38B |
Important Dates
The last earnings date was Tuesday, July 28, 2026.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | Sep 10, 2026 |
Share Statistics
| Current Share Class | 92.30M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +15.76% |
| Shares Change (QoQ) | +8.86% |
| Owned by Insiders (%) | 22.34% |
| Owned by Institutions (%) | 21.72% |
| Float | 36.08M |
Valuation Ratios
The trailing PE ratio is 371.00 and the forward PE ratio is 51.49.
| PE Ratio | 371.00 |
| Forward PE | 51.49 |
| PS Ratio | 1.12 |
| PB Ratio | 2.24 |
| P/TBV Ratio | 2.83 |
| P/FCF Ratio | 46.73 |
| P/OCF Ratio | 10.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.76, with an EV/FCF ratio of 70.21.
| EV / Earnings | 557.43 |
| EV / Sales | 1.68 |
| EV / EBITDA | 18.76 |
| EV / EBIT | 92.28 |
| EV / FCF | 70.21 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 1.17 |
| Debt / EBITDA | 6.51 |
| Debt / FCF | 24.38 |
| Interest Coverage | 0.27 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 0.67% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 3.12M |
| Profits Per Employee | 9,383 |
| Employee Count | 6,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Indoco Remedies has paid 47.80 million in taxes.
| Income Tax | 47.80M |
| Effective Tax Rate | 60.74% |
Stock Price Statistics
The stock price has decreased by -20.41% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -20.41% |
| 50-Day Moving Average | 234.23 |
| 200-Day Moving Average | 223.98 |
| Relative Strength Index (RSI) | 49.86 |
| Average Volume (20 Days) | 17,105 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Indoco Remedies had revenue of INR 18.73 billion and earned 56.30 million in profits. Earnings per share was 0.63.
| Revenue | 18.73B |
| Gross Profit | 13.08B |
| Operating Income | 340.10M |
| Pretax Income | 78.70M |
| Net Income | 56.30M |
| EBITDA | 1.67B |
| EBIT | 340.10M |
| Earnings Per Share (EPS) | 0.63 |
Balance Sheet
The company has 329.90 million in cash and 10.90 billion in debt, with a net cash position of -10.57 billion.
| Cash & Cash Equivalents | 329.90M |
| Total Debt | 10.90B |
| Net Cash | -10.57B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.32B |
| Book Value Per Share | 111.55 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 1.92 billion and capital expenditures -1.48 billion, giving a free cash flow of 447.00 million.
| Operating Cash Flow | 1.92B |
| Capital Expenditures | -1.48B |
| Depreciation & Amortization | 1.33B |
| Net Borrowing | 468.60M |
| Free Cash Flow | 447.00M |
| FCF Per Share | n/a |
Margins
Gross margin is 69.85%, with operating and profit margins of 1.82% and 0.30%.
| Gross Margin | 69.85% |
| Operating Margin | 1.82% |
| Pretax Margin | 0.42% |
| Profit Margin | 0.30% |
| EBITDA Margin | 8.93% |
| EBIT Margin | 1.82% |
| FCF Margin | 2.42% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.09%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.09% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.76% |
| Shareholder Yield | -15.67% |
| Earnings Yield | 0.27% |
| FCF Yield | 2.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Indoco Remedies is 264.00, which is 16.94% higher than the current price. The consensus rating is "Hold".
| Price Target | 264.00 |
| Price Target Difference | 16.94% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on May 17, 2012. It was a forward split with a ratio of 7.5.
| Last Split Date | May 17, 2012 |
| Split Type | Forward |
| Split Ratio | 7.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |